About GCTx
GCTx is a Healthcare company based in Cambridge (United States) founded in 2019 by Cory Smith, Parastoo Khoshakhlagh, and George M Church. Synthetic biology platform for cell programming is developed. GCTx has raised $65 million across 1 funding round from investors including Mubadala, Cormorant and Andreessen Horowitz. The company has 15 employees. Its chief executive, as recorded, is Parastoo Khoshakhlagh. GCTx offers products and services including TFome Platform and iPSC-based Medicines. Its focus areas include Life Sciences, Cell Therapy, Stem Cells and Pluripotent Stem Cells. Its legal entity is GC Therapeutics Inc. Its competitors include Biogen, eGenesis and Kymeratx; 3 of its 3 listed competitors have raised funding.
Company details
GCTx was founded in 2019 in Cambridge, United States, within the synthetic biology sector. A platform for cell programming is provided, centered on the proprietary TFome technology for differentiating pluripotent stem cells. SuperCells are generated through this approach to address specific diseases. Operations are based in the United States, with co-founders including Cory Smith, Parastoo Khoshakhlagh, and George M. Church.
- Total Equity Funding$65M (USD)
in 1 rounds
- Latest Funding Round$65M (USD), Series A
Sep 2024
- InvestorsMubadala
& 2 more
- Employee Count15
Products & Services of GCTx
GCTx offers a comprehensive portfolio of products and services, including TFome Platform and iPSC-based Medicines.
Facilitates rapid iPSC-based medicine development for disease therapies.
Delivers off-the-shelf cell therapies for targeted disease treatment.
Funding Insights of GCTx
GCTx has successfully raised a total of $65M through 1 strategic funding round. The most recent funding activity was a Series A round of $65 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $65M
- Total Rounds 1
- Last Round Series A — $65M
- First Round $65M
(Sep 2024)
- Investors Count 3
All 1 funding rounds of GCTx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2024 | $65M | Series A | – | Cormorant Asset Management |
3 investors in total: 3 institutional.
Investors in GCTx
GCTx has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Mubadala, Cormorant and Andreessen Horowitz.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | a16z.com | |||
Manages diversified investment portfolios across various asset classes. | 1997 | cormorant.com | Boston, United States | |
Sovereign wealth fund of United Arab Emirates | 2002 | mubadala.com | Abu Dhabi, United Arab Emirates |
Investor details for GCTx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GCTx
3 people are tracked at GCTx (3 in leadership); the tracked headcount is 15.
| Name | Role | Group |
|---|---|---|
Cory Smith | Co-Founder | Leadership |
Parastoo Khoshakhlagh | Co-Founder & CEO | Leadership |
George M Church | Co-Founder | Leadership |
Complete people profiles for GCTx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GCTx
2 dated milestones of GCTx across 5 years, from founding to its latest funding, stage changes and deals.
- Founded GCTx is founded.
- Funding First funding round of $65.0M.
Competitors of GCTx
GCTx has 3 listed competitors in our database, 3 of them funded. They include Biogen, eGenesis and Kymeratx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| egenesisbio.com | 2015 | Cambridge, United States | $481.42M | 94 | Gene transplantation platform for humanizing pig cells is developed. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. |
Detailed competitors of GCTx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of GCTx
The website of GCTx (gc-tx.com) receives about 4.6K visits a month.
- Monthly visits4.6K
▼ 4.7% vs previous month
Websites whose visitors overlap most with GCTx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| realtalifesciences.com | 100% | 1.7K | #9,464,639 | View details |
Top companies in Cell Therapy
3 companies that operate in the same segment as GCTx (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gctx
Complete news archive for GCTx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GCTx
GCTx was founded in 2019 and raised its 1st funding round 5 years after it was founded.
GCTx is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Parastoo Khoshakhlagh is the CEO of GCTx, as recorded in our data. They have also founded this company.
GCTx is a funded company, having raised a total of $65M across 1 funding round to date. The company's 1st funding round was a Series A of $65M, raised on Sep 2024.
GCTx has 15 employees.
GCTx was founded in 2019 in Cambridge, United States, within the synthetic biology sector. A platform for cell programming is provided, centered on the proprietary TFome technology for differentiating pluripotent stem cells. SuperCells are generated through this approach to address specific diseases. Operations are based in the United States, with co-founders including Cory Smith, Parastoo Khoshakhlagh, and George M. Church.
GCTx offers TFome Platform and iPSC-based Medicines.
GCTx has 3 investors. Key investors include Mubadala, Cormorant, and Andreessen Horowitz.
GCTx operates through Gc Therapeutics Inc.